All In Biotech

Drug Trial Radar · NCT04709536

A Study of IBI306 in Participants With Hypercholesterolemia

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of IBI306 in Patients With Hypercholesterolemia in China (CREDIT-4)

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

306

Actual

Start

Feb 9, 2021

Primary completion

Nov 9, 2021

Study completion Jan 28, 2022

Sponsor

Sponsor type
Industry
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed for multi-center, double-blind, randomized, placebo-controlled phase III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in hypercholesterolemia patients.

Conditions

  • Hypercholesterolemia

Interventions

  • IBI306Drug

    Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

  • PlaceboDrug

    Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 12Time frame: Baseline to week12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.